Selective Cyclo-Oxygenase-2 Inhibitors and Myocardial Infarction Laurence G. HowesHenry Krum Current Opinion 21 November 2012 Pages: 829 - 835
Hydroxyethylstarch as a Risk Factor for Acute Renal Failure Joachim Boldt Current Opinion 21 November 2012 Pages: 837 - 846
A Benefit-Risk Assessment of Class III Antiarrhythmic Agents Bente BrendorpOle Dyg PedersenLars Køber Review Article 21 November 2012 Pages: 847 - 865
A Benefit-Risk Assessment of Extended-Release Oxybutynin Martin C. Michel Review Article 21 November 2012 Pages: 867 - 876
Oxidation Injury in Patients Receiving HMG-CoA Reductase Inhibitors Helmut SinzingerFahdi ChehneGraziana Lupattelli Original Research Article 21 November 2012 Pages: 877 - 883
Risk Management Strategies in the Physicians’ Desk Reference Product Labels for Pregnancy Category X Drugs Kathleen UhlDianne L. KennedySandra L. Kweder Original Research Article 21 November 2012 Pages: 885 - 892